1
|
Karshieva SS, Babayeva G, Pokrovsky VS, Shlyapnikov YM, Shlyapnikova EA, Bugrova AE, Kononikhin AS, Nikolaev EN, Kanev IL. Antitumor Effect of Bleomycin Nanoaerosol in Murine Carcinoma Model. Molecules 2023; 28:molecules28104157. [PMID: 37241899 DOI: 10.3390/molecules28104157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Revised: 05/11/2023] [Accepted: 05/11/2023] [Indexed: 05/28/2023] Open
Abstract
Bleomycin, which is widely used as an antitumor agent, possesses serious adverse effects such as pulmonary toxicity. Local nanoaerosol deposition for lung cancer treatment is a promising alternative to drug delivery to lung lesions. The aim of this work is to test the hypothesis that bleomycin nanoaerosol can be effectively used to treat multiple lung metastases. To obtain bleomycin nanoaerosol, an aerosol generator based on electrospray of a solution of a nonvolatile substance with gas-phase neutralization of charged aerosol particles was used. Lung metastases in murine Lewis lung carcinoma and B16 melanoma animal models were counted. The effect of inhaled bleomycin nanoparticles on the number and volume of metastases, as well as pulmonary side effects, was investigated. Using a mouse exposure chamber, the dose-dependent effect of inhaled bleomycin on tumor volume was evaluated in comparison with intraperitoneal administration. Bleomycin nanoaerosol reduced the volume of metastases and produced a higher antitumor effect at much lower doses. It has been established that long-term exposure to nanoaerosol with a low dose of bleomycin is capable of suppressing cancer cell growth. The treatment was well tolerated. In the lungs, minor changes were found in the form of focal-diffuse infiltration of the lung parenchyma.
Collapse
Affiliation(s)
- Saida S Karshieva
- Laboratory of Biochemical Pharmacology and Cancer Models, N.N. Blokhin National Medical Research Center of Oncology, 115478 Moscow, Russia
| | - Gulalek Babayeva
- Laboratory of Biochemical Pharmacology and Cancer Models, N.N. Blokhin National Medical Research Center of Oncology, 115478 Moscow, Russia
- Research Institute of Molecular and Cellular Medicine, Patrice Lumumba People's Friendship University, 117198 Moscow, Russia
| | - Vadim S Pokrovsky
- Laboratory of Biochemical Pharmacology and Cancer Models, N.N. Blokhin National Medical Research Center of Oncology, 115478 Moscow, Russia
- Research Institute of Molecular and Cellular Medicine, Patrice Lumumba People's Friendship University, 117198 Moscow, Russia
- Center of Genetics and Life Sciences, Sirius University of Science and Technology, 354340 Sochi, Russia
| | - Yuri M Shlyapnikov
- Institute of Theoretical and Experimental Biophysics, Russian Academy of Science, 142290 Pushchino, Moscow region, Russia
| | - Elena A Shlyapnikova
- Institute of Theoretical and Experimental Biophysics, Russian Academy of Science, 142290 Pushchino, Moscow region, Russia
| | - Anna E Bugrova
- Emanuel Institute for Biochemical Physics, Russian Academy of Science, 119334 Moscow, Russia
| | - Alexey S Kononikhin
- Center of Life Science, Skolkovo Institute of Science and Technology, 121205 Moscow, Russia
| | - Evgeny N Nikolaev
- Center of Life Science, Skolkovo Institute of Science and Technology, 121205 Moscow, Russia
| | - Igor L Kanev
- Institute of Theoretical and Experimental Biophysics, Russian Academy of Science, 142290 Pushchino, Moscow region, Russia
| |
Collapse
|
2
|
Valiulin SV, Onischuk AA, Baklanov AM, Dubtsov SN, Dultseva GG, An’kov SV, Tolstikova TG, Belogorodtsev SN, Schwartz YS. Studies of the Specific Activity of Aerosolized Isoniazid against Tuberculosis in a Mouse Model. Antibiotics (Basel) 2022; 11:antibiotics11111527. [PMID: 36358182 PMCID: PMC9686539 DOI: 10.3390/antibiotics11111527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Revised: 10/20/2022] [Accepted: 10/25/2022] [Indexed: 11/06/2022] Open
Abstract
The aerosol inhalation delivery of isoniazid in mice was investigated, and the specific activity of the aerosol form of isoniazid was studied with the mouse model of tuberculosis infection, the M. tuberculosis H37Rv strain. Aerosol delivery was performed using a laminar-flow horizontal nucleation chamber. The inhalation dose was measured in real-time mode using a diffusion aerosol spectrometer. The mean particle diameter was 0.6 ± 0.03 μm, and the inhalation dose was 5–9 mg/kg. Pharmacokinetic measurements were carried out in nose-only and whole-body chambers. Isoniazid concentration in blood serum and its mass in the lungs were measured as a function of time using high-performance liquid chromatography. Studies of the specific activity of aerosolized isoniazid reveal that treatment with the aerosol lead to the complete recovery of the experimental tuberculosis infection as early as after 28 days after the start of inhalation treatment, while in the animals from the group receiving isoniazid per-orally, sole revivable tuberculosis mycobacteria were detected. Histologic examinations show that only a few macrophagal (nonspecific) granulomas without mycobacteria were detected in the spleen after per-oral and aerosol treatment, the number of granulomas on the 28th day being three times smaller in the latter case. The results show that the developed technique of isoniazid aerosol inhalation may have clinical potential.
Collapse
Affiliation(s)
- Sergey V. Valiulin
- Voevodsky Institute of Chemical Kinetics & Combustion, Russian Academy of Sciences, 630090 Novosibirsk, Russia
- Correspondence:
| | - Andrey A. Onischuk
- Voevodsky Institute of Chemical Kinetics & Combustion, Russian Academy of Sciences, 630090 Novosibirsk, Russia
| | - Anatoly M. Baklanov
- Voevodsky Institute of Chemical Kinetics & Combustion, Russian Academy of Sciences, 630090 Novosibirsk, Russia
| | - Sergey N. Dubtsov
- Voevodsky Institute of Chemical Kinetics & Combustion, Russian Academy of Sciences, 630090 Novosibirsk, Russia
| | - Galina G. Dultseva
- Voevodsky Institute of Chemical Kinetics & Combustion, Russian Academy of Sciences, 630090 Novosibirsk, Russia
| | - Sergey V. An’kov
- Voevodsky Institute of Chemical Kinetics & Combustion, Russian Academy of Sciences, 630090 Novosibirsk, Russia
- N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Russian Academy of Sciences, 630090 Novosibirsk, Russia
| | - Tatiana G. Tolstikova
- Voevodsky Institute of Chemical Kinetics & Combustion, Russian Academy of Sciences, 630090 Novosibirsk, Russia
- N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Russian Academy of Sciences, 630090 Novosibirsk, Russia
| | | | - Yakov Sh. Schwartz
- Novosibirsk Tuberculosis Research Institute, Novosibirsk, 630040 Novosibirsk, Russia
| |
Collapse
|
3
|
Valiulin SV, Onischuk AA, Baklanov AM, An’kov SV, Dubtsov SN, Alekseev AA, Shkil NN, Nefedova EV, Plokhotnichenko ME, Tolstikova TG, Dolgov AM, Dultseva GG. Aerosol Inhalation Delivery of Ceftriaxone in Mice: Generation Procedure, Pharmacokinetics, and Therapeutic Outcome. Antibiotics (Basel) 2022; 11:antibiotics11101305. [PMID: 36289963 PMCID: PMC9598611 DOI: 10.3390/antibiotics11101305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Revised: 09/16/2022] [Accepted: 09/22/2022] [Indexed: 11/25/2022] Open
Abstract
Aerosol inhalation delivery of ceftriaxone in mice was investigated. An ultrasonic nebulizer within the ranges of mean particle diameter 0.5–1.5 μm and mass concentration 0.01–0.6 μg/cm3 was used in inhalation experiments. Pharmacokinetic measurements were carried out using a nose-only chamber. Ceftriaxone concentration in blood serum and its mass in the lungs of mice were measured as a function of time using high-performance liquid chromatography. The body-delivered dose was within the range 3–5 mg/kg. The antibacterial effect of aerosolized ceftriaxone was investigated for mice infected with Klebsiella pneumoniae 82 and Staphylococcus aureus ATCC 25 953. The survival rate for infected mice after the treatment with ceftriaxone aerosol revealed the high antibacterial efficiency of this kind of treatment.
Collapse
Affiliation(s)
- Sergey V. Valiulin
- Voevodsky Institute of Chemical Kinetics and Combustion SB RAS, 3 Institutskaya Str., 630090 Novosibirsk, Russia
- Correspondence:
| | - Andrei A. Onischuk
- Voevodsky Institute of Chemical Kinetics and Combustion SB RAS, 3 Institutskaya Str., 630090 Novosibirsk, Russia
| | - Anatoly M. Baklanov
- Voevodsky Institute of Chemical Kinetics and Combustion SB RAS, 3 Institutskaya Str., 630090 Novosibirsk, Russia
| | - Sergey V. An’kov
- Voevodsky Institute of Chemical Kinetics and Combustion SB RAS, 3 Institutskaya Str., 630090 Novosibirsk, Russia
- Vorozhtsov Institute of Organic Chemistry SB RAS, 9 Lavrentyev Ave., 630090 Novosibirsk, Russia
| | - Sergey N. Dubtsov
- Voevodsky Institute of Chemical Kinetics and Combustion SB RAS, 3 Institutskaya Str., 630090 Novosibirsk, Russia
| | - Alexander A. Alekseev
- Voevodsky Institute of Chemical Kinetics and Combustion SB RAS, 3 Institutskaya Str., 630090 Novosibirsk, Russia
| | - Nikolay N. Shkil
- Siberian Federal Scientific Center of Agro-BioTechnologies RAS, 630501 Krasnoobsk, Russia
| | - Ekaterina V. Nefedova
- Siberian Federal Scientific Center of Agro-BioTechnologies RAS, 630501 Krasnoobsk, Russia
| | - Maria E. Plokhotnichenko
- Voevodsky Institute of Chemical Kinetics and Combustion SB RAS, 3 Institutskaya Str., 630090 Novosibirsk, Russia
| | - Tatyana G. Tolstikova
- Voevodsky Institute of Chemical Kinetics and Combustion SB RAS, 3 Institutskaya Str., 630090 Novosibirsk, Russia
- Vorozhtsov Institute of Organic Chemistry SB RAS, 9 Lavrentyev Ave., 630090 Novosibirsk, Russia
| | - Arseniy M. Dolgov
- Voevodsky Institute of Chemical Kinetics and Combustion SB RAS, 3 Institutskaya Str., 630090 Novosibirsk, Russia
| | - Galina G. Dultseva
- Voevodsky Institute of Chemical Kinetics and Combustion SB RAS, 3 Institutskaya Str., 630090 Novosibirsk, Russia
| |
Collapse
|
4
|
Valiulin SV, Onischuk AA, Baklanov AM, Dubtsov SN, An'kov SV, Shkil NN, Nefedova EV, Plokhotnichenko ME, Tolstikova TG, Dolgov AM, Dultseva GG. Aerosol inhalation delivery of cefazolin in mice: Pharmacokinetic measurements and antibacterial effect. Int J Pharm 2021; 607:121013. [PMID: 34419591 DOI: 10.1016/j.ijpharm.2021.121013] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Revised: 07/26/2021] [Accepted: 08/11/2021] [Indexed: 11/20/2022]
Abstract
Aerosol inhalation delivery of cefazolin, a broad-spectrum first-generation cephalosporin antibiotic, was investigated. Inhalation system based on ultrasonic nebulizer was developed for the generation of dry cefazolin aerosol within mean particle diameter range 0.5-3.0 μm and mass concentration 0.01-3 μg/cm3. Pharmacokinetic measurements were carried out for the aerosolized form of cefazolin delivered in mice using nose-only chamber. Cefazolin concentrations in blood serum and in the lungs of mice were measured as a function of time by means of high performance liquid chromatography. Body-delivered dose depending on particle size, concentration and inhalation time as well as other pharmacokinetic parameters were determined. The antibacterial effect of aerosolized cefazolin was assessed through the aerosol inhalation treatment of mice infected with Klebsiella pneumoniae. Survival rate for infected mice after the treatment with cefazolin aerosol demonstrated high antibacterial efficiency of the inhalation delivery of cefazolin in comparison with intraperitoneal delivery.
Collapse
Affiliation(s)
- S V Valiulin
- Voevodsky Institute of Chemical Kinetics and Combustion SB RAS, Novosibirsk, 630090, Russia
| | - A A Onischuk
- Voevodsky Institute of Chemical Kinetics and Combustion SB RAS, Novosibirsk, 630090, Russia
| | - A M Baklanov
- Voevodsky Institute of Chemical Kinetics and Combustion SB RAS, Novosibirsk, 630090, Russia
| | - S N Dubtsov
- Voevodsky Institute of Chemical Kinetics and Combustion SB RAS, Novosibirsk, 630090, Russia
| | - S V An'kov
- Voevodsky Institute of Chemical Kinetics and Combustion SB RAS, Novosibirsk, 630090, Russia; Vorozhtsov Institute of Organic Chemistry SB RAS, Novosibirsk 630090, Russia
| | - N N Shkil
- Siberian Federal Scientific Center of Agro-Biotechnologies RAS, Krasnoobsk 630501, Russia
| | - E V Nefedova
- Siberian Federal Scientific Center of Agro-Biotechnologies RAS, Krasnoobsk 630501, Russia
| | - M E Plokhotnichenko
- Voevodsky Institute of Chemical Kinetics and Combustion SB RAS, Novosibirsk, 630090, Russia
| | - T G Tolstikova
- Voevodsky Institute of Chemical Kinetics and Combustion SB RAS, Novosibirsk, 630090, Russia; Vorozhtsov Institute of Organic Chemistry SB RAS, Novosibirsk 630090, Russia
| | - A M Dolgov
- Voevodsky Institute of Chemical Kinetics and Combustion SB RAS, Novosibirsk, 630090, Russia
| | - G G Dultseva
- Voevodsky Institute of Chemical Kinetics and Combustion SB RAS, Novosibirsk, 630090, Russia
| |
Collapse
|
5
|
Kogel U, Wong ET, Szostak J, Tan WT, Lucci F, Leroy P, Titz B, Xiang Y, Low T, Wong SK, Guedj E, Ivanov NV, Schlage WK, Peitsch MC, Kuczaj A, Vanscheeuwijck P, Hoeng J. Impact of whole-body versus nose-only inhalation exposure systems on systemic, respiratory, and cardiovascular endpoints in a 2-month cigarette smoke exposure study in the ApoE -/- mouse model. J Appl Toxicol 2021; 41:1598-1619. [PMID: 33825214 PMCID: PMC8519037 DOI: 10.1002/jat.4149] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2020] [Revised: 02/02/2021] [Accepted: 02/03/2021] [Indexed: 11/09/2022]
Abstract
Cigarette smoking is one major modifiable risk factor in the development and progression of chronic obstructive pulmonary disease and cardiovascular disease. To characterize and compare cigarette smoke (CS)-induced disease endpoints after exposure in either whole-body (WB) or nose-only (NO) exposure systems, we exposed apolipoprotein E-deficient mice to filtered air (Sham) or to the same total particulate matter (TPM) concentration of mainstream smoke from 3R4F reference cigarettes in NO or WB exposure chambers (EC) for 2 months. At matching TPM concentrations, we observed similar concentrations of carbon monoxide, acetaldehyde, and acrolein, but higher concentrations of nicotine and formaldehyde in NOEC than in WBEC. In both exposure systems, CS exposure led to the expected adaptive changes in nasal epithelia, altered lung function, lung inflammation, and pronounced changes in the nasal epithelial transcriptome and lung proteome. Exposure in the NOEC caused generally more severe histopathological changes in the nasal epithelia and a higher stress response as indicated by body weight decrease and lower blood lymphocyte counts compared with WB exposed mice. Erythropoiesis, and increases in total plasma triglyceride levels and atherosclerotic plaque area were observed only in CS-exposed mice in the WBEC group but not in the NOEC group. Although the composition of CS in the breathing zone is not completely comparable in the two exposure systems, the CS-induced respiratory disease endpoints were largely confirmed in both systems, with a higher magnitude of severity after NO exposure. CS-accelerated atherosclerosis and other pro-atherosclerotic factors were only significant in WBEC.
Collapse
Affiliation(s)
- Ulrike Kogel
- Philip Morris International Research and Development, Philip Morris Products S.A., Neuchatel, Switzerland
| | - Ee Tsin Wong
- Philip Morris International Research Laboratories Pte. Ltd., Science Park II, Singapore
| | - Justyna Szostak
- Philip Morris International Research and Development, Philip Morris Products S.A., Neuchatel, Switzerland
| | - Wei Teck Tan
- Philip Morris International Research Laboratories Pte. Ltd., Science Park II, Singapore
| | - Francesco Lucci
- Philip Morris International Research and Development, Philip Morris Products S.A., Neuchatel, Switzerland
| | - Patrice Leroy
- Philip Morris International Research and Development, Philip Morris Products S.A., Neuchatel, Switzerland
| | - Bjoern Titz
- Philip Morris International Research and Development, Philip Morris Products S.A., Neuchatel, Switzerland
| | - Yang Xiang
- Philip Morris International Research and Development, Philip Morris Products S.A., Neuchatel, Switzerland
| | - Tiffany Low
- Philip Morris International Research Laboratories Pte. Ltd., Science Park II, Singapore
| | - Sin Kei Wong
- Philip Morris International Research Laboratories Pte. Ltd., Science Park II, Singapore
| | - Emmanuel Guedj
- Philip Morris International Research and Development, Philip Morris Products S.A., Neuchatel, Switzerland
| | - Nikolai V Ivanov
- Philip Morris International Research and Development, Philip Morris Products S.A., Neuchatel, Switzerland
| | - Walter K Schlage
- Biology Consultant, Max-Baermann-Str. 21, Bergisch Gladbach, Germany
| | - Manuel C Peitsch
- Philip Morris International Research and Development, Philip Morris Products S.A., Neuchatel, Switzerland
| | - Arkadiusz Kuczaj
- Philip Morris International Research and Development, Philip Morris Products S.A., Neuchatel, Switzerland
| | - Patrick Vanscheeuwijck
- Philip Morris International Research and Development, Philip Morris Products S.A., Neuchatel, Switzerland
| | - Julia Hoeng
- Philip Morris International Research and Development, Philip Morris Products S.A., Neuchatel, Switzerland
| |
Collapse
|
6
|
Valiulin SV, Onischuk AA, Dubtsov SN, Baklanov AM, An'kov SV, Plokhotnichenko ME, Tolstikova TG, Dultseva GG, Rusinov VL, Charushin VN, Fomin VM. Aerosol Inhalation Delivery of Triazavirin in Mice: Outlooks for Advanced Therapy Against Novel Viral Infections. J Pharm Sci 2021; 110:1316-1322. [PMID: 33249050 PMCID: PMC7833544 DOI: 10.1016/j.xphs.2020.11.016] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2020] [Revised: 11/18/2020] [Accepted: 11/18/2020] [Indexed: 01/21/2023]
Abstract
Under pandemic-caused emergency, evaluation of the potential of existing antiviral drugs for the treatment of COVID-19 is relevant. Triazavirin, an antiviral drug developed in Russia for per-oral administration, is involved in clinical trials against SARS-CoV-2 coronavirus. This virus has affinity to epithelial cells in respiratory tract, so drug delivery directly in lungs may enhance therapeutic effect and reduce side effects for stomach, liver, kidneys. We elaborated ultrasonic method of triazavirin aerosol generation and investigated the inhalation delivery of this drug in mice. Mean particle size and number concentration of aerosol used in inhalation experiments are 560 nm and 4 × 105 cm-3, respectively. Aerosol mass concentration is 1.6 × 10-4 mg/cm3. Inhalation for 20 min in a nose-only chamber resulted in 2 mg/kg body delivered dose and 2.6 μg/mL triazavirin concentration in blood plasma. Elimination rate constant determined in aerosol administration experiments was ke = 0.077 min-1, which agrees with the value measured after intravenous delivery, but per-oral administration resulted in considerably lower apparent elimination rate constant of pseudo-first order, probably due to non-linear dependence of absorption rate on triazavirin concentration in gastrointestinal tract. The bioavailability of triazavirin aerosol is found to be 85%, which is about four times higher than for per-oral administration.
Collapse
Affiliation(s)
- Sergey V Valiulin
- Voevodsky Institute of Chemical Kinetics and Combustion, SB RAS, Novosibirsk 630090, Russia
| | - Andrey A Onischuk
- Voevodsky Institute of Chemical Kinetics and Combustion, SB RAS, Novosibirsk 630090, Russia
| | - Sergey N Dubtsov
- Voevodsky Institute of Chemical Kinetics and Combustion, SB RAS, Novosibirsk 630090, Russia
| | - Anatoly M Baklanov
- Voevodsky Institute of Chemical Kinetics and Combustion, SB RAS, Novosibirsk 630090, Russia
| | - Sergey V An'kov
- Vorozhtsov Institute of Organic Chemistry, SB RAS, Novosibirsk 630090, Russia
| | | | | | - Galina G Dultseva
- Voevodsky Institute of Chemical Kinetics and Combustion, SB RAS, Novosibirsk 630090, Russia.
| | - Vladimir L Rusinov
- Postovskii Institute of Organic Synthesis, UrB RAS, Yekaterinburg 620137, Russia
| | - Valery N Charushin
- Postovskii Institute of Organic Synthesis, UrB RAS, Yekaterinburg 620137, Russia
| | - Vasily M Fomin
- Khristianovich Institute of Theoretical and Applied Mechanics, SB RAS, Novosibirsk 630090, Russia
| |
Collapse
|